The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.
It’s an exciting time for gynecologic malignancies, as treatment options continue to be explored, said Maurie Markman, M.D., resident of Medicine and Science, Cancer Treatment Centers of America.
Three PARP inhibitors are now approved for the treatment of ovarian cancer — Zejula (niraparib), Lynparza (olaparib) and Rubraca (rucaparib) – in the maintenance setting. Now, checkpoint inhibitors, a type of immunotherapy agent, are the next to be explored, according to Markman. An increase in molecular testing will continue to move the field into an era of precision medicine, where each patient will have a specific treatment plan that is tailored to their disease.